Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a Decrease of 3.9 Perce ...

Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161 LEVEL UP, a Phase 3b/4 head-to-head study, compared upadacitinib to dupilumab for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis who had inadequate response to systemic therapy or when use of those therapies was inadvisable1 The safety profile of upadacitinib was consistent wi ...

The healthcare sector has gained momentum lately on investors’ rush to safety in a volatile stock market. The sector is non-cyclical in nature, which, in turn, provides a cushion to the portfolio. Additionally, escalating geopolitical tension and an uncertain Fed have raised the appeal for defensive bets.As such, ultra-popular ETFs, Health Care Select Sector SPDR Fund (XLV) , Vanguard Health Care ETF (VHT) , iShares U.S. Healthcare ETF (IYH) and Fidelity MSCI Health Care Index ETF (FHLC) are up modestly bet ...

After a rather weak 2023, the drug and biotech sector made a comeback initially in 2024 amid a slew of takeover deals. However, the sector has slowed down thereafter, mostly due to macroeconomic pressure.Concerns around the economy and inflation, regular pipeline setbacks and generic/biosimilar competition for blockbuster drugs are some headwinds of drug developers. Uncertainty about the impact of Medicare drug price negotiations and the Federal Trade Commission’s (FTC) scrutiny of M&A deals in the sector r ...

The first-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported mixed first-quarter results as it beat estimates for earnings but missed the same for sales.Yesterday, Swiss pharma giant Novartis AG reported better-than-expected first-quarter financial results, as its earnings and sales both ...

Because dividend investing has such an impressive track record of beating non-dividend-paying stocks, many investors buy Dividend Aristocrats for their portfolios. It’s not a bad strategy to begin with.Dividend Aristocrats are stocks on the S&P 500 that have consistently raised their payouts for 25 years or more. Studies show stocks that initiate a dividend and then raise them over time have outperformed all other stocks over time. Yet, there are limits to the strategy.As Walgreens Boots Alliance (NASDAQ:WB ...

Analysts on Wall Street project that AbbVie (ABBV) will announce quarterly earnings of $2.26 per share in its forthcoming report, representing a decline of 8.1% year over year. Revenues are projected to reach $11.99 billion, declining 1.9% from the same quarter last year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Ahead of a company's earnings disclos ...

AbbVie (ABBV) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 26. On the o ...

智通财经APP获悉，艾伯维(ABBV.US)的收购标的Cerevel Therapeutics(CERE.US)周四宣布，其每日一次的帕金森病口服候选药物tavapadon在一项作为联合疗法的关键性三期试验中达成主要目标。 该公司说，针对帕金森病晚期成人患者的TEMPO-3研究表明，在主要终点方面，他伐帕东与脑部疗法左旋多巴联合用药与安慰剂加左旋多巴相比，具有临床意义和显著的统计学差异。 这项为期27周、针对507名患者的研究将无运动障碍总“开启”时间与基线假设相比的变化作为主要终点，结果显示，与安慰剂对照组(1.7小时对0.6小时)相比，服药组的“开启”时间增加了1.1小时。 此外，与安慰剂对照组相比，他伐帕东加左旋多巴组的关键次要终点“关闭”时间也具有有统计学意义的显著缩短。 关于安全性，该公司补充说，研究药物的耐受性良好，大多数不良反应程度为轻度至中度。 Cerevel希望利用这些研究结果支持未来的他伐帕东监管申请。该候选药物在帕金森病中的两项后期单一疗法试验的顶线数据预计将于2024年下半年公布。 去年12月，艾伯维同意以87亿美元收购Cerevel。由于Cerevel是一家领先的精神分裂症药物开发商 ...

−     Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen1−     The safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were identified1 −     The clinical program ref ...